Clinical Trials Logo

Disease Susceptibility clinical trials

View clinical trials related to Disease Susceptibility.

Filter by:

NCT ID: NCT04390269 Recruiting - Clinical trials for Genetic Predisposition to Disease

Immunogenetics Predictors With COVID-19

Start date: September 10, 2020
Phase:
Study type: Observational

Background: There is a current worldwide outbreak of the novel coronavirus Covid-19 which originated from Wuhan in China and has now spread to 6 continents including 210 countries. There is still a lack of any report about severe acute respiratory syndromes (SARS-CoV-2) genetic polymorphisms which are associated with the susceptibility to infection. In addition, gene polymorphisms of MBL (mannose-binding lectin) associated with antigen presentation are related to the risk of SARS-CoV infection. Aim: To investigate the association of different genetic markers of different mechanisms of viral pathogenesis with the outcome of COVID-19. Methods: The study will include one hundred patients diagnosed as COVID-19. Biological blood samples will be taken for routine diagnostic analysis, routine molecular testing using Real-time polymerase chain reaction (PCR), Allelic discrimination and genotyping analysis. Outcome: Different genetic markers could play a role in the outcome and prognosis of COVID-19 viral infection.

NCT ID: NCT04353973 Recruiting - Cancer Clinical Trials

Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Cancer Patients

eReach
Start date: August 17, 2020
Phase: N/A
Study type: Interventional

This study aims to determine if web-based eHealth delivery of pre-test and/or post-test counseling in cancer patients and/or those at risk for cancer can provide equal or improved cognitive and affective outcomes when compared to the standard of care delivery model.

NCT ID: NCT04332848 Recruiting - Clinical trials for Helicobacter Pylori Infection

Susceptibility Testing Guided Versus Empirical Therapy for Refractory H. Pylori Infection

Start date: July 24, 2020
Phase: Phase 4
Study type: Interventional

Aim: Therefore, we aimed to 1. compare the efficacy of susceptibility testing guided therapy vs. empirical therapy in the third-line eradication for refractory H. pylori infection 2. assess the long-term impact of eradication therapy on the antibiotic resistance and microbiota of the gut flora and the metabolic factors. Methods: This will be a multi-center, open labeled trial Patients: 360 patients with failure to H. pylori eradication for at least two times will be enrolled Determination of antibiotic resistance of H. pylori: Agar dilution test will be used to determine the minimum inhibitory concentrations of levofloxacin, tetracycline, rifabutin, and clarithromycin to guide the selection of antibiotics. Treatment regimens and assignment: Eligible patients will be randomized to receive either one of the treatments (A) Susceptibility testing guided therapy or (B) Empirical therapy Outcome Measurement: Primary End Point: Eradication rate will be evaluated according to Intent-to-treat (ITT) analyses. Secondary End Point: 1. Eradication rate according to per protocol analysis (PP analysis); 2. Frequency of adverse effects.

NCT ID: NCT04315727 Recruiting - Rare Diseases Clinical Trials

Identification of the Genetic Causes of Rare Diseases With Negative Exome Findings

Start date: February 1, 2021
Phase: N/A
Study type: Interventional

The GENOME + project will enroll patients (n = ca. 100) and their healthy parents with unclear molecular cause of the disease, suspected genetic cause of the disease and previous detailed molecular analysis like Whole Exome Sequencing (WES) did not lead to the identification of the disease causing mechanism. As well healthy parents of those affected for trio analysis (exception of one parent is not available for the study).

NCT ID: NCT04280666 Recruiting - Clinical trials for Hereditary Colorectal Cancer

Next-generation Sequencing of Colorectal Cancer Somatic Cells to Guide Genetic Susceptibility Gene Mutations Screening.

Start date: June 20, 2019
Phase:
Study type: Observational

This is a prospective, single-center, clinical study.This study is to evaluate the feasibility of genetic susceptibility screening based on the detection of tumor tissue mutations by a NGS panel.

NCT ID: NCT04265937 Recruiting - Breast Cancer Clinical Trials

ScreenIng of Genetic Susceptibility Genes for Breast Cancer Patients in CHinese communiTies

SIGHT
Start date: July 1, 2019
Phase:
Study type: Observational

This is a community-based prospective study and the research object is breast cancer patients. It is planned to take the community as the unit to inform and collect the breast cancer patients who voluntarily participate to carry out the detection of BRCA1, BRCA2, PTEN, CHEK2 and PALB2 genes through the community health service center.

NCT ID: NCT04171635 Recruiting - MRI Scans Clinical Trials

Quantitative Susceptibility Mapping (QSM) to Guide Iron Chelating Therapy

Start date: December 16, 2019
Phase:
Study type: Observational

The overall goal of this research is to help develop a new magnetic resonance (MR) method, Quantitative Susceptibility Mapping (QSM), to improve the measurement of liver iron concentrations without the need for a liver biopsy. Measurement of liver iron is important to diagnose and treat patients who have too much iron in their bodies (iron overload). Liver iron measurements by current MRI methods (R2 and R2*) can be inaccurate because of the effects of fat, fibrosis and other abnormalities. QSM should not be affected by these factors and should be free of these errors. In this study, MRI measurements (QSM, R2 and R2*) of iron in patients before liver transplant will be compared with chemical analysis of iron in liver explants (livers removed from patients undergoing liver transplant). The liver explants would otherwise be discarded. Investigators expect that this study will show that the new MRI method, QSM, is superior to the current MRI methods, R2 and R2*.

NCT ID: NCT04141462 Recruiting - Cancer Clinical Trials

EXOME Analysis Position in the Strategy of Genetic Predisposition Factors Identification in Early-onset Cancer

EX²TRICAN
Start date: October 7, 2019
Phase: N/A
Study type: Interventional

5 to 10% of cancers are due to the presence of a constitutional genetic alteration. It can be inherited from parents (family form) or by accident, in the first moments of life after fertilization (sporadic form). In both cases, this genetic alteration is constitutional and transmissible to descendants. It is hereditary. When an hereditary early form is suspected, several well-known genes generally involved in genetic predispositions to cancer are found by a technique called " gene panel ". However, this analysis does not always identify the genetic predisposing factors for cancer. New techniques called "high-throughput exome sequencing (SHD-E)", allow more than the analysis of the the gene panel. These analysis allow to identify alterations in other genes that could contribute to the development of cancer. The objective of the Ex²trican study is to show, from patients with early cancer (sporadic or familial form), that this approach to exome sequencing can be effective to identify new genetic risk of cancer, when the first panel analysis of genes is negative.

NCT ID: NCT04139096 Recruiting - Thyroid Neoplasms Clinical Trials

Genetic Susceptibility to Radiation Induced Thyroid Cancer

Start date: September 22, 2019
Phase:
Study type: Observational

Case control on thyroid cancer occuring in a cohort of 7300 subjects treated during their childhood, mostly by radiotherapy, for a skin Angioma at Gustave Roussy, Villejuif France between 1947 and 1973. This case control study, which is included in a larger european project, aims to investigate the DNA variant interacting with the risk of radiation induced thyroid cancer after irradiation. The sutdy is planed to include about 30 cases and 30 controls. Matching criteria are date of birth, gender, and age at irradiation.

NCT ID: NCT04100863 Recruiting - Clinical trials for Autism Spectrum Disorder

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Autism

Start date: March 2, 2020
Phase:
Study type: Observational [Patient Registry]

This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records regarding autism.